While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week [Yahoo! Finance]
MediumReport
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week [Yahoo! Finance]
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome [Yahoo! Finance]
LowReport
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome [Yahoo! Finance]
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
LowReport
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $80.00 to $79.00. They now have a "buy" rating on the stock.
LowReport
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $80.00 to $79.00. They now have a "buy" rating on the stock.
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
LowReport
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: